Zymeworks to Host Fourth Quarter and Full Year 2021 Results Conference Call

VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will report its fourth quarter and full year 2021 financial results after market close on February 24^th, 2022. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on February 24^th, 2022 at 4:30 p.m. ET.

Conference Call and Webcast Information:

• Telephone: 800-319-4610 (U.S. or Canada) or +1-604-638-5340 (international)
• The event will be webcast live with dial-in details and webcast replays available on Zymeworks’ website at http://ir.zymeworks.com/events-and-presentations.

About Zymeworks Inc.
Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, zanidatamab, is a novel Azymetric™ HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks’ second clinical candidate, ZW49, is a novel bispecific HER2‑targeted antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks’ proprietary ZymeLink™ linker and cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with global biopharmaceutical companies. For more information on our ongoing clinical trials visit www.zymeworksclinicaltrials.com. For additional information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220208006164/en/

Investor Inquiries:

Ryan Dercho, Ph.D.

(604) 678-1388

ir@zymeworks.com



Jack Spinks

(604) 678-1388

ir@zymeworks.com



Media Inquiries:

Diana Papove

(604) 678-1388

media@zymeworks.com

Source: Zymeworks Inc.

FAQ

When will Zymeworks report its financial results for Q4 2021?

Zymeworks will report its fourth quarter and full year 2021 financial results after market close on February 24, 2022.

What time is the Zymeworks conference call on February 24, 2022?

The Zymeworks conference call is scheduled for 4:30 p.m. ET on February 24, 2022.

What is Zymeworks' lead clinical candidate?

Zymeworks' lead clinical candidate is zanidatamab, a bispecific antibody targeting HER2 in solid tumors.

What other clinical candidate is Zymeworks developing?

Zymeworks is also developing ZW49, a bispecific HER2-targeted antibody-drug conjugate currently in Phase 1 development.

Where can I watch the Zymeworks conference call?

The conference call will be webcast live and can be accessed on Zymeworks' website.